Table 1.

Patient demographics and baseline clinical characteristics

Characteristic	No. of patients (n = 29)
Age, y
Median	63
Range	38-80
Male sex	55
International Staging System stage
I	10 (34)
II	15 (52)
III	4 (14)
Albumin, g/dL
Median	3.62
Range	2.6-4.5
Paraprotein
IgG	13 (45)
IgA	9 (31)
Free light chain	15 (52)
Other (IgD and IgM)	0 (0)
Eastern Cooperative Oncology Group performance status
0	16 (55)
1	11 (38)
2	2 (7)
No. of previous therapies
Median	3
Range	1-6
Type of therapy
Thalidomide only	4 (14)
Lenalidomide only	13 (45)
Lenalidomide + thalidomide	11 (38)
No previous thalidomide or lenalidomide	1 (3)
Bortezomib	19 (66)
Autologous stem cell transplantation	20 (69)

IgG indicates immunoglobulin G; and IgA, immunoglobulin A.